If you are interested in weight loss support you can start a consultation here
Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M, SUMMIT Trial Study Group
Cureus 7 , e302 (2015)
Overall, we identified that adjunctive use of bestatin (protease inhibitor), imatinib (tyrosine kinase inhibitor), roflumilast [phosphodiesterase-4 inhibitor (PDE-4)], or palacaparib [Poly(ADP-ribose) polymerase 1, PARP-1 inhibitor] significantly reduced both mortality (compared to the control arm, adjunctive dexamethasone) and neurological deficits (compared to the control arm, TB treatment alone)
But as with any compound, especially one not yet clinically approved for human use , its safety depends on: The quality of the peptide The accuracy of the dose and administration The duration and purpose of your use Your individual health profile and risk tolerance While BPC-157 exhibits an extraordinary safety profile in animals, its long-term safety in humans remains to be fully established. Sikiric, P
, ,